A Phase 2 Randomized Clinical Trial to Examine the Efficacy of Carbon-Ion Radiotherapy Plus Camrelizumab As Salvage Treatment for Locally Recurrent Nasopharyngeal Carcinoma
Latest Information Update: 03 May 2022
At a glance
- Drugs Camrelizumab (Primary) ; Gemcitabine; Nedaplatin
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- 24 Apr 2022 Status changed from not yet recruiting to recruiting.
- 03 Jan 2021 Planned initiation date changed from 20 Dec 2020 to 20 Jan 2021.
- 27 Dec 2020 Induction chemotherapy with the regimen of gemcitabine plus nedaplatin added to study protocol.